# A Study to Evaluate the Effect of Dapagliflozin on Blood Glucose Level and Renal Safety in Patients With Type 2 Diabetes

Study · id `cardio:ct-nct02413398` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02413398](<https://clinicaltrials.gov/study/NCT02413398>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02413398

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 321 participants.

## Technical summary

Registry record NCT02413398. Randomized; double masking; primary purpose treatment. Start 2015-06-15 (actual); primary completion 2017-11-07 (actual). Results posted on 2018-10-31.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 321 participants (enrolled count; ClinicalTrials.gov record NCT02413398, source copy `cardio:ctgov-nct02413398-2018-10-31`, retrieved 2026-10-26)
- Started: 2015-06-15 (actual) (ClinicalTrials.gov record NCT02413398, source copy `cardio:ctgov-nct02413398-2018-10-31`, retrieved 2026-10-26)
- Primary completion: 2017-11-07 (actual) (ClinicalTrials.gov record NCT02413398, source copy `cardio:ctgov-nct02413398-2018-10-31`, retrieved 2026-10-26)
- Completion: 2017-11-07 (actual) (ClinicalTrials.gov record NCT02413398, source copy `cardio:ctgov-nct02413398-2018-10-31`, retrieved 2026-10-26)
- Results first posted: 2018-10-31 (ClinicalTrials.gov record NCT02413398, source copy `cardio:ctgov-nct02413398-2018-10-31`, retrieved 2026-10-26)
- Countries: United States; Bulgaria; Canada; Czechia; Italy; Poland; Spain; Sweden (ClinicalTrials.gov record NCT02413398, source copy `cardio:ctgov-nct02413398-2018-10-31`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02413398-2018-10-31`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study to Evaluate the Effect of Dapagliflozin on Blood Glucose Level and Renal Safety in Patients With Type 2 Diabetes
- Acronym: DERIVE
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): Dapagliflozin 10 mg
- Intervention (Drug): Matching Placebo for Dapagliflozin
- Lead sponsor: AstraZeneca
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Dapagliflozin (`cardio:dapagliflozin`)
- Registry intervention is a member of this class by a sourced record link: SGLT2 inhibitors (drug class) (`cardio:sglt2-inhibitors`)
- Registry lists this organization as the lead sponsor: AstraZeneca (`cardio:astrazeneca`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study (`cardio:pubmed-29888547`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 0aa0e0b5eaac9f166230d40b99c1b76d9189d502ca7f6033adf65e510e68386d
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
